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Abstract
Background: Diabetic retinopathy is one of the most common microvascular complications of diabetes and one of 
the major causes of adult visual impairment in national surveys in Taiwan. This study aimed to identify the healthcare 
costs of Taiwan's National Health Insurance program on behalf of diabetic patients with stable or progressive 
retinopathy.
Methods: A retrospective cohort study was conducted with 4,988 medication-using diabetic retinopathy subjects ≥ 
40 years of age under National Health Insurance Program coverage between 2000 and 2004. Study cohort subjects 
were recorded as having diabetic retinopathy according to ICD-9-CM codes. States of diabetic retinopathy were 
strategically divided into stable and progressive categories according to subjects' conditions at follow-up in 2004. 
Expenditures were calculated and compared for the years 2000 and 2004.
Results: During the 4-year follow-up (2000 through 2004), 4,116 subjects (82.5%) of 4,988 diabetic subjects were in the 
stable category, and 872 (17.5%) were in the progressive category. Average costs of those in the normal category 
increased by US $48 from US $1921 in 2000 to US $1969 in 2004 (p = 0.594), whereas costs for those progressing from 
normal to non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) increased by US 
$1760, from US $1566 in 2000 to US $3326 in 2004 (p < 0.001). The PDR category had the highest average costs at US 
$3632 in 2000. The NPDR-to-PDR category experienced the greatest increase in costs at US $3482, from US $2723 in 
2000 to US $6204 in 2004 (p = 0.042), and the greatest percentage of increase at 2.3% (2.2% when adjusted by 
comparing to normal category).
Conclusions: This large-scale longitudinal study provides evidence that increased healthcare costs are associated with 
progressive diabetic retinopathy among diabetic NHI enrollees in Taiwan.
Background
Diabetes mellitus is a common, chronic disease among
adults, with a worldwide prevalence estimated at 4% in
1995 and projected to rise to 5.4% by the year 2025 [1]. In
Taiwan, diabetes is one of the most common chronic dis-
eases, with a prevalence rate among adults estimated at
between 4.9 and 8.0% from 1985 to 1995 [2-4]. As a
result, both the demand for and the costs of medical care
for diabetic patients is increasing [5].
Healthcare costs for diabetics are more than double the
costs of those without diabetes in the United States [6]
and the occurrence of major diabetes-related complica-
tions in type 2 diabetics patients is associated with
increased average medical costs annually [7,8]. Diabetic
retinopathy is one of the most common microvascular
complications of diabetes and is one of the major causes
of adult visual impairment in national surveys conducted
in both Taiwan [9] and the United States [10].
Increased healthcare costs attract the attention of pol-
icy makers seeking strategies to reduce medical costs.
Despite the enormity of the problem, nationwide data
about the costs of treating diabetic patients with diabetic
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retinopathy are still limited. A common source of admin-
istrative data is health insurance claims data associated
with private or public health insurance programs. In Tai-
wan, 96% of all residents have been enrolled in the
National Health Insurance (NHI) program since 1996. In
this study, we used these administrative claims data to
identify the costs of the NHI program paid on behalf of
diabetic patients with either stable or progressive retin-
opathy.
Methods
Data source and study population
In Taiwan, the National Health Insurance (NHI) Program
began on March 1, 1995. As of 2007, 22.6 million of Tai-
wan's 23 million persons were enrolled in this program.
Therefore, the NHI Program has accumulated 23.8 mil-
l i o n  a d m i n i s t r a t i v e  a n d  c l a i m s  r e c o r d s .  I n  o r d e r  t o
respond to current and emerging issues rapidly and effec-
tively, the National Health Research Institutes (NHRI)
cooperated with the NHI Bureau (NHIB) to establish and
maintain an NHI research database. The NHRI safe-
guards the privacy and confidentiality of subjects and
routinely transfers insurance health data from the NHIB
to health researchers for analysis, with the aim of improv-
ing the health of Taiwan's citizens. Data analysed in this
study were also retrieved from the National Health Insur-
ance Research Database. Access to research data has been
approved by the Review Committee of the NHRI. The
NHRI provides a unique validated database of medical
claims from 200,432 random subjects, representing about
1% of the population, for use in health insurance studies.
These data consisted of inpatient and ambulatory care
records, as well as registration files, and resulted in the
establishment of an academic, retrospective cohort
gr oup.  T his  a ca de m ic c oho rt  da ta base  has  bee n t es t ed
and no notable differences were found in age, sex, or
medical costs for all enrollees [11]. Likewise, several stud-
ies have been conducted to evaluate the prevalence, inci-
dence, and other associated factors of various diseases
using the NHI research database [12-14].
Since 1999, the NHRI database has used the Interna-
tional Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) for outpatient and inpatient
diagnostic coding. By searching these electronic records
and pharmacy prescriptions in similar fashion to a previ-
ous study [15], individuals were identified who used med-
ications typically prescribed for diabetes (insulin or oral
hypoglycemic agents) during the period of observation.
For the yearly data set in both 2000 and 2004, subjects in
the study cohort were recorded as having diabetic retin-
opathy if we found the following ICD-9-CM codes during
the search of administrative or outpatient data: 362.0
(non-proliferative diabetic retinopathy, NPDR), and 362.0
(proliferative diabetic retinopathy, PDR). The normal sta-
tus was recorded when no evidence of diabetic retinopa-
thy was found. The states of diabetic retinopathy were
strategically divided into stable and progressive catego-
ries according to the subjects' conditions at follow-up in
2004.
Estimation of medical costs for diabetes
All estimates of medical costs, including copayments,
were calculated in New T aiwan dollars (NT$). F ee-for -
service costs included outpatient and inpatient care, pre-
scription drugs, and laboratory fees. Costs represented
healthcare expenditures for an individual for the whole
year, not focusing exclusively on those associated with
diabetes or diabetic retinopathy. Outpatient services
included outpatient visits, emergency department visits,
end-stage renal dialysis, preventive services, dental care,
home healthcare, and traditional Chinese medicine treat-
ments. Inpatient care costs were calculated over a one-
year period in both 2000 and 2004. The costs in this study
did not include services that might have been provided
but were not covered by NHI. Indirect costs of diabetes
such as lost productivity due to disability or premature
death were not estimated.
Excess costs associated with changes in diabetic retin-
opathy were measured and compared as average annual
costs for 2000 and 2004. Changes in annual costs associ-
ated with diabetic retinopathy were estimated by compar-
ing mean medical costs in 2000 and 2004 for the two
main categories of stable and progressive retinal status.
These included two subcategories in the stable group
(normal-to-normal, NPDR-to-NPDR, and PDR-to-PDR),
and three subcategories in the progressive group (nor-
mal-to-NPDR and PDR, NPDR-to-PDR).
Statistical analysis
The statistical significance of differences identified in
mean costs was evaluated using the paired t test because
claim years for the same individual were assumed to be
inherently related.
Results
In our study population, the number of medication-using
diabetic subjects ≥ 40 years of age was 4,988 under NHI
coverage in 2000. The expenditures of all subjects were
calculated and compared for the years 2000 and 2004.
The characteristics of these subjects are presented in
Table 1. Among all subjects, 2,642 (53.0%) were female,
and 2,192 (44.0%) were considered elderly (age 65 and
older).
Changing status of diabetic retinopathy
Table 2 shows 4,116 (82.5%) of 4,988 diabetic subjects
who were in the stable category, and 872 (17.5%) who
were in the progressive category during the 4-year follow-
up. Among those 4,116 stable individuals, 91.6% subjectsWoung et al. BMC Health Services Research 2010, 10:136
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were classified as normal, 5.1% as NPDR, and 3.3% as
PDR. Among 872 in the progressive category, 93.5% had
no diabetic retinopathy in 2000, but had progressed to
NPDR or PDR by 2004; 6.5% had NPDR in 2000 and pro-
gressed to PDR in 2004.
Changes in costs by progression of diabetic retinopathy
Table 2 also depicts the costs of medical care in NHI pro-
gram enrollees in the two groups, PDR and NPDR. The
presence and progression of diabetic retinopathy were
associated with significant increases in costs of the NHI
program. For example, average costs in the normal-to-
normal category increased only NT$1,543 (US $48), from
NT$62,218 (US $1921) in 2000 to NT$63,761 (US $1969)
in 2004, whereas costs for those progressing from nor-
mal- to-NPDR or PDR increased NT$57,020 ($1760),
from NT$50,712 (US $1566) in 2000 to NT$107,732 (US
$3326) in 2004.
The normal category in both 2000 and 2004 had the
lowest costs, and smaller relative increases in costs from
2000 to 2004. The PDR category had the highest average
costs of NT$117,630 (US $3632) in 2000, but the NPDR-
to-PDR category experienced the greatest increase in
costs ( NT$112,779, US $3482), from NT$88,182 (US
$2723) in 2000 to NT$200,961 (US $6204) in 2004.
Regarding the percentage of increased costs between
2000 and 2004, the normal-to-NPDR-or-PDR category
was 2.1% (2.1, adjusted by comparing to the normal cate-
gory) and the NPDR-to-PDR category was 2.3% (adjusted
to 2.2%), which were relatively higher than those in the
stable group (Table 2).
Table 1: Characteristics of study population in 2000.









Table 2: Medical Costs for Diabetic Retinopathy between 2000 and 2004.
Group Baseline/Final Status n % Year Total Cost* 2004/2000 ratio 
(adjusted ratio)
Excess Cost* P Value**
Stable
Normal/Normal 3772 75.6 2000 62, 218 1.02 (reference = 1) 1, 543 0.594
2004 63, 761
NPDR/NPDR 208 4.2 2000 75, 506 1.38 (1.35) 29, 316 0.086
2004 104, 822
PDR/PDR 136 2.7 2000 117, 630 1.55 (1.50) 64, 123 0.036
2004 181, 753
Progressive
Normal/NPDR or PDR 815 16.4 2000 50, 712 2.12 (2.07) 57, 020 <0.001
2004 107, 732
NPDR/PDR 57 1.1 2000 88, 182 2.28 (2.22) 112, 779 0.042
2004 200, 961
Abbreviations: NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
* Total cost & excess cost in NT dollars
**P value for t-testWoung et al. BMC Health Services Research 2010, 10:136
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Discussion
Our current study is a longitudinal study that aimed to
provide cost estimates associated with different severities
of diabetic retinopathy in Taiwan. The number of medi-
cation-using diabetic subjects ≥ 40 years of age was 4,988
under NHI coverage in 2000. Of these 4,988 diabetic sub-
jects, 82.5% were in the stable category, and 17.5% were in
the progressive category during the 4-year follow-up. The
normal category had the lowest costs and smaller relative
increases in costs. The PDR category had the highest
average costs in 2000, but the NPDR-to-PDR category
experienced the greatest increase in costs from 2000 to
2004.
Any analysis of claims data is subject to significant limi-
tations that have been well defined in the literature
[16,17]. However, few studies have been published
regarding the reliability and validity of such secondary
data. In assessing diagnoses of diabetes, Lin et al. found
that the accuracy of NHI claims data was 74.6% [18].
Variations in estimating the costs of diabetes care might
result from alternative definitions for selecting diagnoses
or combinations of diagnoses [19].
In Taiwan, the direct costs of healthcare for diabetic
patients was 11.5% of the total national healthcare costs
and was 4.3 times higher than the average cost of care for
non-diabetic individuals from 1997 to 1998 [20].
In our study, diabetic subjects with diabetic retinopathy
in 2000 had higher 2000 costs than those diabetic sub-
jects with a normal retinal status in a cross-sectional
view, but the normal-to-normal category had smaller rel-
ative increases in costs from 2000 to 2004 in a longitudi-
nal view. One cross-sectional study conducted in
Germany in 2002 also revealed that costs associated with
diabetic retinopathy tend to increase as diabetic retinopa-
thy progresses, being highest in patients with proliferative
diabetic retinopathy and lowest in patients with mild,
non-proliferative diabetic retinopathy [21]. One study
conducted in the United States demonstrated that only
part of the substantial expenditures associated with dia-
betic retinopathy, and with PDR in particular, are due to
ophthalmic care [22].
In our study, subjects with proliferative diabetic retin-
opathy had the highest average costs in both 2000 and
2004, and subjects who progressed from NPDR to PDR
experienced the greatest increases in costs. This evidence
implies that strategies aimed at preventing and mitigating
diabetic complications such as diabetic retinopathy are
likely to be relative to long-term reductions in medical
costs.
We acknowledge several limitations in our study. First,
our analysis only included costs of medical care incurred
by the NHI program in Taiwan. Second, we did not adjust
for co-morbid diseases, and just focused on the relation-
ship between overall medical costs and severities of dia-
betic retinopathy. Third, technological changes and
economic inflation constitute a dynamic process. Diag-
nosis and treatment in 2000 may be somewhat different
than that in 2004 as well as into the future, and cost esca-
lation due to inflation may also be a factor. Both the
results of absolute excess costs and relative percentage of
increased costs should be taken into consideration.
Fourth, misclassification bias in both the diagnosis and
the grading of diabetic retinopathy should be considered
when using claims data.
Conclusions
In conclusion, we provide nationwide, large-scale, and
longitudinal evidence that increased healthcare costs are
associated with progressive diabetic retinopathy among
diabetic NHI enrollees in Taiwan. It implies that strate-
gies aimed at preventing and mitigating diabetic compli-
c a t i o n s  s u c h  a s  d i a b e t i c  r e t i n o p a t h y  a r e  l i k e l y  t o  b e
relative to long-term reductions in medical costs.
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